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following criteria: (1) treatment, as opposed to secondary prophylaxis, of VTE; and 
2) documentation of resource use and costing methods. We extracted data on study 
characteristics, outcomes, costs, and cost drivers associated with VTE treatment. 
RESULTS: We identiﬁed 17 economic evaluations of VTE treatment: three cost-
minimization studies, eight cost-of-illness studies, two cost-effectiveness studies, and 
four cost-utility studies. Studies assessed the economic burden of VTE treatment from 
a payor perspective for various sites of care and types of treatments. Only two studies 
included indirect costs; no studies from a caregiver perspective were identiﬁed. The 
mean number of inpatient hospital days varied from 4.4 to 11, depending on type of 
VTE and treatment. Readmissions for deep vein thrombosis (DVT) ranged from 6.7% 
to 19.2%. Annual mean inpatient costs for DVT ranged from $5779 (1999 USD) to 
$16,600 (2004 USD) per patient. Acute care costs of uncomplicated DVT (i.e. no 
pulmonary embolism (PE), bleeding, or heparin-induced thrombocytopenia [HIT]) 
were estimated as $3486 (1997 USD) compared with $11,189 for DVT with major 
bleed and $9476 for DVT with PE. These outcomes were sensitive to key cost drivers 
(e.g. length of stay, readmissions, and complications such as bleeding, HIT, and post-
thrombotic syndrome). CONCLUSIONS: Despite differences in methodology, studies 
showed that costs associated with treatment of VTE impose major ﬁnancial burdens 
on payors. Additional research is needed to quantify the economic burden of VTE 
treatment from patient and caregiver perspectives.
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OBJECTIVES: The patients, who had undergone Per-cutaneous Transluminal Coro-
nary Angioplasty (PTCA) along with stenting (Drug eluting stent or bare metal stent), 
were analyzed and compared for cost and outcomes for period of one year. 
METHODS: The clinical and cost related details of the patients who had undergone 
PTCA with stenting were collected retrospectively from a private tertiary care hospital. 
The cost of re-admissions within period of one year was added to initial cost to get 
the total cost spent for revascularization after one year. RESULTS: A total of 251 
patients who had undergone PTCA with stenting were included in the study. Average 
length of stay was found to be 3.7 ± 0.14 (Mean ± SEM) days. The average cost of 
the procedure was INR 3,10,000 ± 700 where the cost of PTCA package varied from 
INR 75,000 to INR 1,15,000. Average number of Bare Metal Stent (BMS) and Drug 
Eluting Stent (DES) inserted per patient were 1.56 and 1.33 respectively. The average 
initial cost for the patients who received only BMS (60 patients) and only DES (175 
patients) were INR 2,13,522 ± 9,386 and INR 3,34,550 ± 9,161 respectively. Total 
34 patients (13.5%) were readmitted for cardiac related reason within a year. Out of 
34, 20 patients (BMS: 16.67%, DES: 5.7%) underwent repeat revascularization within 
a year. One patient suffered from stent thrombosis that received a DES initially. The 
cost after one year for BMS and DES groups were INR 3,18,606 and INR 3,69,978. 
CONCLUSIONS: One-year outcomes revealed that rates of repeat revascularization 
were lower for DES group as compared to BMS group but the total cost of revascu-
larization remained higher for DES group.
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OBJECTIVES: The approaching availability of lower-cost generic angiotensin receptor 
blockers (ARBs) may affect formulary policies by encouraging patients responding 
well to ARB valsartan to switch to another ARB with lower prescription costs. Thus, 
this study aims to estimate the economic impact of switching from valsartan (including 
valsartan-based single pill combinations) to other ARBs without apparent medical 
reasons. METHODS: Patients with essential hypertension and at least six months of 
continuous valsartan treatment, free of hospitalization, cardiovascular events, renal 
events or ARB-associated adverse events were identiﬁed from the large administrative 
claims database MarketScan from January 1, 2004 to March 31, 2008. Those who 
subsequently switched to a different ARB with at least a 5% copayment decrease 
(switchers) were matched to those who did not switch (maintainers) according to 
propensity score quintiles and selected baseline characteristics. Matched switchers and 
maintainers were compared in terms of medication discontinuation, health care 
resource use and costs during the 6 months following the index ﬁll. RESULTS: A total 
of 99,926 valsartan maintainers and 2,150 switchers (with a mean copayment decrease 
of $16.5 per month) were identiﬁed and matched. After matching, switching from 
versus maintaining valsartan was associated with an 8% higher risk of medication 
discontinuation (P < 0.008), 19.1 additional outpatient visits/100 patients (P = 0.002) 
and 9.3 additional hypertension-related inpatient days/100 patients (P = 0.030). Con-
currently, switching from versus maintaining valsartan was associated with higher 
total medical costs by $748/patient (P < 0.001), driven largely by higher costs for 
hypertension-related medical services by $492/patient (P = 0.004). CONCLUSIONS: 
Hypertension patients maintained on valsartan who switched to a different ARB with 
a lower copayment experienced substantial increases in medication discontinuation, 
health care resource use and costs compared to those who maintained valsartan treat-
ment. Formulary policies that encourage such non-medical switching may therefore 
lead to increased total costs.
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OBJECTIVES: This study assessed the impact of worsening renal function (WRF) 
during hospitalization on health care resource utilization in hospitalized heart failure 
(HF) patients. METHODS: A retrospective, longitudinal study using patient-level data 
provided by Geisinger Health System MedMining database that captures clinical and 
cost data for inpatient and outpatient episodes, inpatient medication use and phar-
macy claims. It included adult hospitalized patients with HF as a primary diagnosis 
deﬁned via relevant ICD-9 code(s). Patients were excluded if they had no previous 
HF, or were admitted for acute coronary syndromes or cardiac surgery at or within 
30 days prior to the ﬁrst HF-related hospitalization (index hospitalization). WRF was 
deﬁned as ≥0.3 mg/dL increase in serum creatinine (SCr) at any time during hospital-
ization. Univariate analyses were used to assess the association between WRF and 
health care resource utilization. A priori statistical signiﬁcance level of 0.05 was used 
for these analyses. RESULTS: Of 5803 hospitalized patients with primary HF diag-
nosis, 827 (14%) patients fulﬁlled all pre-speciﬁed inclusion and exclusion criteria. 
Mean age (± SD) was 73.5 ± 14.1 years, 43% were male, 98% Caucasians and ≥80% 
had some renal impairment at admission based on MDRD eGFR <90 ml/min/1.73 m2. 
Average admission SCr was 1.4 ± 0.9 mg/dL. Nearly 33% of patients exhibited WRF 
during index hospitalization. As compared to hospitalized HF patients w/o WRF, 
those with WRF had greater prevalence of diabetes (54% vs. 43%), reduced baseline 
eGFR (43.7 ± 29.7 vs. 62.2 ± 35.3 ml/min/1.73 m2), elevated potassium levels (4.3 ± 
0.7 vs.4.2 ± 0.7 mEq/L), greater BNP at baseline (844.7 ± 820.8 vs. 794.9 ± 947.2 pg/
ml), higher total inpatient cost including medications, physician and hospital services, 
labs, procedures ($20,829 ± $26,686 vs. $13,445 ± $20,392, p < 0.001) and greater 
length of hospital stay (8.2 ± 6.8 vs. 5.7 ± 5.5 days, P < 0.001). CONCLUSIONS: 
Among hospitalized HF patients, occurrence of WRF was associated with an increase 
in the hospitalization cost by 58% and length of stay by 41% versus absence of WRF.
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OBJECTIVES: To assess if there are differences in the number of restenosis after the 
placement of sirolimus-eluting stent vs. paclitaxel-eluting stent and their related costs. 
METHODS: A literature review was conducted to identify either meta-analysis or 
randomized clinical trials (RCT) which compared sirolimus-eluting stent (SES) and 
paclitaxel-eluting stent (PES). The outcome of interest was angiographic restenosis 
after stent placement since this is an important surrogate indicator that may predict 
late mortality. We decided to model the results of the meta-analysis that evaluated 6 
RCTs and comprised 3`669 patients which concluded that angiographic restenosis was 
less frequently in patients in the SES (9.3%) vs. PES (13.1%) (Kastrati, 2005). An 
analytic-decision model was developed according to local guidelines (Vianna, 2007) 
and the Brazilian payer’s perspective. Resource usage was raised in a panel with 
hospitals. A micro-costing technique was applied. Unit costs were based on published 
sources (CBHPM 5th, PROAHSA, Brasíndice and SIMPRO) and reported in 2010 
Brazilian Reais (USD 1 = R$ 1.75). Only direct medical costs were considered. Time 
horizon was one year, so discounting was not applied. A 100,000 cohort was assumed 
considering a revascularization incidence of 932/100,000 (Ryen, 2009). A one-way 
sensitivity analyses was performed. RESULTS: In our hypothetical cohort SES patients 
had fewer cases of restenosis (86 vs. 122) when compared with PES patients. Due to 
that better outcome, total cost for the SES group was lower to the one found in the 
PES group (R$ 31,627 vs. R$ 34,127). CONCLUSIONS: Results suggest SES patients 
had a 29% risk reduction of restenosis compared with PES patients. SES may also 
offer a 7.32% potential reduction in costs for the payer.
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OBJECTIVES: Compared to patients with an authorized discharge, patients who 
self-discharge AMA may be at higher risk for a future hospital readmission. Thus, the 
cost of discharges AMA may be alternatively examined by considering readmissions 
costs. The objective of this study is to estimate the relationship between discharges 
AMA and hospital readmissions costs in the cardiovascular disease (CVD) setting. 
METHODS: This cross-sectional study uses conﬁdential inpatient hospital discharge 
